Page 6 - Lantern Pharma News Today

Lantern Pharma Inc. , a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of... | March 28, 2023

EF Hutton Acquisition Co. I reaffirmed their buy rating on shares of Lantern Pharma (NASDAQ:LTRN – Get Rating) in a report issued on Tuesday morning, Benzinga reports. The firm currently has a $11.00 price target on the stock. Lantern Pharma Price Performance Shares of Lantern Pharma stock opened at $4.52 on Tuesday. Lantern Pharma has […]

DALLAS--(BUSINESS WIRE)--Feb 27, 2023--

Presented by D CEO and Dallas Innovates, program honorees included David C. Williams of AT&T, Andrew Bender of DZS, Celanese Corp, Hedera and Swirlds, and more.

Panna Sharma: Thank you, Nicole. Good afternoon, everyone. And welcome to our third quarter 2022 earnings call.

According to research conducted by PricewaterhouseCoopers (PwC), 45% of the economic gains by the end of this decade will be driven by the enhancement in AI technology that will provide impetus to consumer...

DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its...

15.11.2022 - Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics ...

Global Pancreatic Cancer Treatment Market is valued at USD 2.61 Billion in 2021, and it is anticipated to attain a value of USD 3.78 Billion by 2028, at a...

14.09.2022 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (A.I.) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery ... Seite 1